Trial Profile
Phase 3, Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Oct 2019
Price :
$35
*
At a glance
- Drugs Olopatadine (Primary) ; Olopatadine (Primary)
- Indications Allergic conjunctivitis
- Focus Registrational; Therapeutic Use
- Sponsors Alcon
- 04 Apr 2014 New trial record
- 24 Jul 2013
- 06 Jun 2013